Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison

74,489 patients from 9 randomized trials, including 21,717 (29%) smokers

Antiplatelet treatment (clopidogrel, prasugrel, or ticagrelor) in various regimens (e.g., clopidogrel vs aspirin, clopidogrel plus aspirin vs aspirin alone, double dose vs standard dose clopidogrel, prasugrel plus aspirin vs clopidogrel plus aspirin, ticagrelor plus aspirin vs clopidogrel plus aspirin)

Control groups (aspirin alone, standard dose clopidogrel, or clopidogrel plus aspirin depending on the trial)

Composite clinical outcome of cardiovascular death, myocardial infarction, and strokecomposite